Raltegravir (MK-0518)

Catalog No.S2005

For research use only.

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. It shows greater than 1000-fold selectivity for HIV-1 IN over several related Mg2+-dependent enzyme such as HCV polymerase, HIV reverse transcriptase, HIV RNaseH and human α-, β-, γ-polymerases.

Raltegravir (MK-0518) Chemical Structure

CAS No. 518048-05-0

Selleck's Raltegravir (MK-0518) has been cited by 54 publications

Purity & Quality Control

Choose Selective Integrase Inhibitors

Other Integrase Products

Biological Activity

Description Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. It shows greater than 1000-fold selectivity for HIV-1 IN over several related Mg2+-dependent enzyme such as HCV polymerase, HIV reverse transcriptase, HIV RNaseH and human α-, β-, γ-polymerases.
Features The 1st approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor.
Targets
Integrase (S217Q PFV) [1]
(Cell-free assay)
Integrase (WT PFV) [1]
(Cell-free assay)
40 nM 90 nM
In vitro

PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM, indicating a ~twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme. [1] Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31?0 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95 of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity. [2] Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium. [3] Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication. [4] In acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MT4 NGf4O4hCdnSrdnnyZYwh[XO|YYm= MXfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25uIFXDOVAhRSByLkCwNVQh|ryPLh?= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV2MUeyOkc,OTh3NEG3NlY9N2F-
MT-4 NI\lOI1CdnSrdnnyZYwh[XO|YYm= M4\seWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDNWE01KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36sJGVEPTBiPTCwMlAxOThizszNMi=> MkTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThzNkC1NlEoRjF6MU[wOVIyRC:jPh?=
MT-4 M4O2[2FvfGm4aYLhcEBie3OjeR?= NHS1SFZCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB3\XOrY4XsZZIhe3SxbXH0bZRqeyC4aYL1d{BINXC|ZYXkc5R6eGWmIFj1cYFvKGmvbYXuc4Rm\mmlaXXuZ5khfmm{dYOgbY5n\WO2ZXSgbY4hcHWvYX6gUXQuPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIILldIxq[2G2aX;uMEBGSzVyIE2gNE4xODJizszNMi=> MlXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThzNkC1NlEoRjF6MU[wOVIyRC:jPh?=
MT2 MniyRY51cX[rcnHsJIF{e2G7 NHfKWZg{KHSxIESg[IF6ew>? NH;ZdGxCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKE2WMjDj[YxteyCvZXHzeZJm\CCjZoTldkA{KHSxIESg[IF6eyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjByMjFOwG0v M1T3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN{MEixNFExLz5|MkC4NVAyODxxYU6=
MT-2 M{jRN2FvfGm4aYLhcEBie3OjeR?= Ml\jRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDNWE0zKGOnbHzzJIJ6KHS5bzDmc4xlKGSrbIX0bY9vKG2ndHjv[EBqdiCycnXz[Y5k\SCxZjCxNEUhTkKVLDDFR|UxKD1iMD6wNFMh|ryPLh?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFyNECxNEc,OTlzMESwNVA9N2F-
MT2 NV[zV4J6SW62aY\pdoFtKGG|c3H5 NVfFUVI5PSCmYYnz M4DMUmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQzKGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDjbIVucWy3bXnu[ZNk\W6lZTDpckBxemW|ZX7j[UBw\iCoZYThcEBjd3[rbnWgd4VzfW1uIFXDOVAhRSByLkCwOEDPxE1w NH64NoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK4OVM5QSd-MUmyPFU{QDl:L3G+
HOS MonNRY51cX[rcnHsJIF{e2G7 Mof0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCqYYLic5Jqdmdid3ns[E11gXCnIHnueIVoemG|ZTDpcoZm[3SnZDDpckBpfW2jbjDIU3Mh[2WubIOsJGVEPTBiPTCwMlAxPCEQvF2u M2\pXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEmzNFY3Lz5{MUS5N|A3PjxxYU6=
HOS MnPPRY51cX[rcnHsJIF{e2G7 MUSzJIhzew>? MUXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDD3bYxlNXS7cHWgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKGmwZnXjeIVlKGmwIFjPV{Bk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7II\pdoFtKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxKD1iMD6wNFQh|ryPLh?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUixOkc,OjR2N{G4NVY9N2F-
MT2 M2fiXGFvfGm4aYLhcEBie3OjeR?= NXPvTVlFPSCmYYnz Mk\DRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB|QjDpckBOXDJiY3XscJMh[W[2ZYKgOUBl[Xm|LDDFR|UxKD1iMD6wNFYh|ryPLh?= NFvKVHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEKwO|M6QCd-MUiyNFc{QTh:L3G+
MT-4 MmPpRY51cX[rcnHsJIF{e2G7 MmqzRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXKDFiUlnOJIhiemKxcnnu[{BqdnSnZ4Lhd4Uh\2WwZTDpcoZm[3SnZDDpckBOXC12IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUCgQUAxNjByNjFOwG0v MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5OEexN{c,OTh|N{i3NVM9N2F-
MT4 M4q0TWFvfGm4aYLhcEBie3OjeR?= M4nLdmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCkeTDNWHQh[XO|YYmsJGVEPTBiPTCwMlAxPiEQvF2u M{Xqc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|E5Lz5{NEmwNFcyQDxxYU6=
MT4 MnjZRY51cX[rcnHsJIF{e2G7 MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYuOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO|ZXSgZZMheHKxdHXjeIlwdiCjZ3HpcpN1KH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZpkhVVSWIHHzd4F6NCCHQ{WwJF0hOC5yME[g{txONg>? M3;JelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{mzN|YxLz5{NEe5N|M3ODxxYU6=
MT4 NXjZRodqSW62aY\pdoFtKGG|c3H5 NFzEWYJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNiaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCxiRVO1NEA:KDBwMEC2NUDPxE1w M{HEOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEe5NlA3Lz5{MES3PVIxPjxxYU6=
MT4 NXL0R|E2TnWwY4Tpc44h[XO|YYm= MXOxJIhz M1PWPGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFjJWlEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy|IIXzbY5oKGOnbHzzJJBz\S2rbnP1ZoF1\WRid3n0bEBkd22yb4Xu[EBnd3JiMTDodkBu\WG|dYLl[EA1KGSjeYOgdI9{fCC4aYLhcEBqdm[nY4Tpc44h[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6wNFYzKM7:TT6= Mlu5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkOxN|UoRjJ{OU[zNVM2RC:jPh?=
MT4 NU[4d3diSW62aY\pdoFtKGG|c3H5 M{fKXWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpd2enbnnjbZR6KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFA3PCEQvF2u NIHnNJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS0O|YzOSd-MUm0OFc3OjF:L3G+
MT-4 Mlz4RY51cX[rcnHsJIF{e2G7 MUDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYhOSCQTESuN{Bp[XKkb4LpcochcW62ZXfyZZNmKEx5NF2gcZV1[W62IHnu[oVkfGWmIHnuJIh2dWGwIF3UMVQh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFA4KM7:TT6= NUS0eY93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO|g4OTNpPkG4N|c5PzF|PD;hQi=>
MT4 MkfrRY51cX[rcnHsJIF{e2G7 M1\GbGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCkeTDNWHQh[XO|YYmsJGVEPTBiPTCwMlAxPzhizszNMi=> NV:3XHNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVExQTVpPkK4PVUyODl3PD;hQi=>
MT-4 NFnt[VNCdnSrdnnyZYwh[XO|YYm= MV\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UMVQh[2WubIOgZpkhfHexIH\vcIQh\GmudYTpc44hdWW2aH;kJIlvKHC{ZYPlcoNmKG:oIEGwKUBHSlNuIFXDOVAhRSByLkCwPEDPxE1w NFnpd3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGwOFAyOCd-MUmxNFQxOTB:L3G+
MT-4 MXzBcpRqfmm{YXygZZN{[Xl? Mnn6RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXKDFiTly0MlMhcW62ZXfyZZNmKFN{M{DOJI12fGGwdDDpcoZm[3SnZDDpckBpfW2jbjDNWE01KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCkeTDNWHQh[XO|YYmsJGVEPTBiPTCwMlAxQSEQvF2u NWexZolFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO|g4OTNpPkG4N|c5PzF|PD;hQi=>
MT4 MmDGRY51cX[rcnHsJIF{e2G7 NYTZc5BvPDhidH:gO|IhcHK| MWrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCneIDy[ZN{cW6pIFfGVEBqdmO3YnH0[YQh\m:{IES4JJRwKDd{IHjyd{BqdiCjYoPlcoNmKG:oIEWwKUBvd3KvYXygbJVu[W5ic3XyeY0h[nlibYXseIlxdGVicn;1coQhfmm{YXygdoVxdGmlYYTpc44hc2mwZYTpZ5Mh[XO|YYmsJGlRKD1iMD6wNFkh|ryPLh?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7N{m2OUc,OjZ|OUe5OlU9N2F-
FL-4 MXrBcpRqfmm{YXygZZN{[Xl? NHLZcoVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBH\WyrbnWgbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyCrbn\lZ5Rm\CCrbjDjZZQhTkxvNDDj[YxteyCjc4Pld5Nm\CCjczD2bZJidCCUTlGgdJJw\HWldHnvckBjgSCUVD3xVGNTNCCHQ{WwJF0hOC5yMEm5PEDPxE1w NHvzZ4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixN|c{Oid-MkS4NVM4OzJ:L3G+
MT-4 MXHBcpRqfmm{YXygZZN{[Xl? NFjjXJVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZiMTDSTW4hcGG{Yn;ybY5oKGmwdHXndoF{\SCpZX7lJIlv\mWldHXkJIlvKE2WLUSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSCjZoTldkAzOCCyYYPzZYdmeyC|ZXzlZ5Rm\CCrbjDwdoV{\W6lZTDv[kBkd22yb4Xu[EwhTUN3MDC9JFAvODFizszNMi=> MlTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|N{i3NVMoRjF6M{e4O|E{RC:jPh?=
HeLa NGW2U25CdnSrdnnyZYwh[XO|YYm= MXK0PEBpenN? NVXQWVRlSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYMTDs[Y51cX[rcnHsJJBienSrY3zld{Bqdm[nY4Tl[EBqdiCqdX3hckBJ\UyjIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JJNx\WO2cn;mcJVwem:vZYTyfUwhUUN3MDC9JFAvODFizszNMi=> MofHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUizNFAoRjJ{OEW4N|AxRC:jPh?=
cat FL-4 MkHlRY51cX[rcnHsJIF{e2G7 MVu3JIRigXN? NFz3ZohCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBH\WyrbnWgbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyCrbn\lZ5Rm\CCrbjDjZZQhTkxvNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFch\GG7czDifUByfWGwdHn0ZZRqfmViUmStVGNTKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMTFOwG0v MmPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEK4OFkoRjJ3N{CyPFQ6RC:jPh?=
cat FL-4 MmnYRY51cX[rcnHsJIF{e2G7 NFvxW2w4KGSjeYO= NEjrZ21CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBHUVZiaX7m[YN1\WRiaX6gZ4F1KE[OLUSgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKH[rcnHsJHJPSSCuZY\lcEBu\WG|dYLl[EBi\nSncjC3JIRigXNiYomgdXJVNVCFUjDhcoFtgXOrczygSWM2OCB;IECuNFEh|ryPLh?= NIXwfYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUO5OVUyOCd-M{GzPVU2OTB:L3G+
MT4 NVi0SJVkSW62aY\pdoFtKGG|c3H5 MYXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYzKFKRRDCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbD3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODFzIN88UU4> NV7PTmxFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVExQTVpPkK4PVUyODl3PD;hQi=>
MT4 MVTBcpRqfmm{YXygZZN{[Xl? MorRRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCycn;0[YN1cW:wIHHnZYlve3RidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBu\WG|dYLl[EA2KGSjeYOgdI9{fCCrbn\lZ5Rqd25iYomgUXRVKGG|c3H5MEBGSzVyIE2gNE4xOTF5IN88UU4> M37mUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUSwOFYzLz5{OUm0NFQ3OjxxYU6=
MT4 Mo\SRY51cX[rcnHsJIF{e2G7 NGX2TnNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCrbjDoeY1idiCPVESgZ4VtdHNuIFXDOVAhRSByLkCxN{DPxE1w Ml;hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MUezOFIoRjF6NEG3N|QzRC:jPh?=
MT4 Mlz4RY51cX[rcnHsJIF{e2G7 MVLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SsJGVEPTBiPTCwMlAyOyEQvF2u NYn1U2ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2N|A4PjVpPkKwOlMxPzZ3PD;hQi=>
MT4 Mo\oRY51cX[rcnHsJIF{e2G7 NFTIbZhCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiYomgUXRVKGG|c3H5MEBGSzVyIE2gNE4xOTNizszNMi=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ{N{W1NEc,OjF{Mke1OVA9N2F-
BL21(DE3) MYDGeY5kfGmxbjDhd5NigQ>? MmW4NUBpeg>? MkL0TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDITXYuOSCrboTl[5Jie2Vic4ThcoQhfHKjboPm[ZIh[WO2aY\peJkh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUhFTTNrIHPlcIx{KHW|aX7nJFMzWC2uYXLlcIVlKESQQTDzeYJ{fHKjdHWgZYZ1\XJiMTDodkBjgSCmZX7zbZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNE4xOTNizszNMi=> NXnSZ|VURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OVE4PzFpPkK2OFUyPzdzPD;hQi=>
MT-4 MVHBcpRqfmm{YXygZZN{[Xl? MY\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYhOSCQTESuN{BqdnSnZ4Lhd4UhTTl{UTDteZRidnRiaX7m[YN1\WRiaX6gbJVu[W5iTWStOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7LDDFR|UxKD1iMD6wNVUh|ryPLh?= NXTpZ4x3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO|g4OTNpPkG4N|c5PzF|PD;hQi=>
MT4 MkDxRY51cX[rcnHsJIF{e2G7 MoTiOUBl[Xm| M4DtfGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIlv[3WkYYTl[EBnd3JiNTDkZZl{KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFE2KM7:TT6= NEj2NYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUOyOFU3Oid-M{GzNlQ2PjJ:L3G+
MT2 NEW0dWNCdnSrdnnyZYwh[XO|YYm= M2r0eGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXiCrbjDNWFIh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiM{WgcYcwdUxiaIXtZY4he2W{dX2gZYxjfW2rbjygSWM2OCB;IECuNFE3KM7:TT6= NXrCO4RqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyNFc{QThpPkG4NlA4Ozl6PD;hQi=>
MT-4 MVnBcpRqfmm{YXygZZN{[Xl? NFL0bJI2KGSjeYO= M2jXXmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KvUGFKKGmwZnXjeIVlKGmwIHj1cYFvKE2WLUSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JI1m[XO3cnXkJJN2en[rdnHsJIFnfGW{IEWg[IF6eyCkeTDNWHQh[XO|YYmsJGVEPTBiPTCwMlAyPiEQvF2u MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NEmxPUc,OjRzMkS5NVk9N2F-
HeLa-CD4-LTR-beta-gal MnnrRY51cX[rcnHsJIF{e2G7 MUixJIRigQ>? NV\NWVN6SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYLUGgN2IhcW6oZXP0[YQhcW5iaIXtZY4hUGWOYT3DSFQuVFSULXLleIEu\2GuIHPlcIx{KGGodHXyJFEh\GG7IHL5JJNx\WO2cn;zZ49xcWNiYX7hcJl{cXNuIFXDOVAhRSByLkCxOkDPxE1w NWK0eJRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlkzPTZpPkK1OlI6OjV4PD;hQi=>
MT-2 Mk[wRY51cX[rcnHsJIF{e2G7 MmDFRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDNWE0zKGOnbHzzJIJ6KHS5bzDmc4xlKGSrbIX0bY9vKG2ndHjv[EBqdiCycnXz[Y5k\SCxZjCxNEUhTkKVLDDIV2Eh[W6mIHHsdIhiOS2DR2CsJGVEPTBiPTCwMlAyQCEQvF2u M4HRPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUC0NFExLz5zOUGwOFAyODxxYU6=
MT4 NVjyU2dHSW62aY\pdoFtKGG|c3H5 NESxVnRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIlvKGi3bXHuJG1VPCClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEUhcGWjdD3hZ5RqfmG2ZXSg[oV1[WxiYn;2bY5mKHOncoXtMEBKSzl3IE2gNE4xOTlizszNMi=> NHHJb2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe2N|c2OSd-MUi3OlM4PTF:L3G+
MT2 MUnBcpRqfmm{YXygZZN{[Xl? NUTITItbPSCmYYnz NWHpeVRoSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDJiY3XscJMh[W[2ZYKgOUBl[Xm|IHL5JINp\W2rbIXtbY5me2OnbnPlJIlvKHC{ZYPlcoNmKG:oIHj1cYFvKHOncoXtJIFt[nWvaX6sJGVEPTBiPTCwMlAzKM7:TT6= NGi2[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK4OVM5QSd-MUmyPFU{QDl:L3G+
MT4 NFnRT5dCdnSrdnnyZYwh[XO|YYm= NVi2ZmsxPSCmYYnz MmKxRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOiCUT1SgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIlv[3WkYYTl[EBnd3JiNTDkZZl{KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFIh|ryPLh?= NXjnUJpyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNlQ2PjJpPkOxN|I1PTZ{PD;hQi=>
TZM-b1 M2HBfGFvfGm4aYLhcEBie3OjeR?= MVGxJIhz MlPBRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXNTFiTly0MlMhcW6oZXP0[YQhcW5iaIXtZY4hXFqPLXKxJINmdGy|IIDy[ZRz\WG2ZXSg[o9zKDFiaIKg[o9tdG:5ZXSgZpkhfmm{YXygbY5n\WO2aX;uJI1m[XO3cnXkJIFnfGW{IEKg[IF6eyCkeTDDVHJIKGG|c3H5MEBKSzVyIE2gNE4xOjFizszNMi=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRyOEKyOEc,Ojh2MEiyNlQ9N2F-
CEM-SS M3XLVWFvfGm4aYLhcEBie3OjeR?= NHr5TIE3KGSjeYO= Mn\1RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDDSW0uW1NiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJJZqenW|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiYX\0[ZIhPiCmYYnzJIJ6KE2WUzDhd5NigSxiRVO1NEA:KDBwMEKzJO69VS5? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ6M{K2NUc,Ojd{OEOyOlE9N2F-
HeLa NFHqWnJCdnSrdnnyZYwh[XO|YYm= Mmn2N{Bl[Xm| MlPKRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDI[WxiKGOnbHzzJIV5eHKnc4PpcochS0R2LVzUVk1j\XSjLXfhcEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIILldIxq[2G2aX;uJIFnfGW{IEOg[IF6eyCkeTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyIE2gNE4xOjN4IN88UU4> NWTGfJZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFQzPzBpPkK0Olg1OjdyPD;hQi=>
HeLa-CD4-LTR-beta-gal NFzKTJhCdnSrdnnyZYwh[XO|YYm= M4m5e2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXi1zIEPCJIlv\mWldHXkJIlvKGi3bXHuJGhmVGFvQ1S0MWxVWi2kZYThMYdidCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIILldIxq[2G2aX;uJIJ6KFOyZXP0doFO[XhiR1XNTW5KNViVIIDsZZRmKHKnYXTldkBidmGueYPpd{whTUN3MDC9JFAvODJ|NjFOwG0v NFX5VXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NVk3OCd-MkW5OlE6PjB:L3G+
HeLa M164bWFvfGm4aYLhcEBie3OjeR?= MX6yJIRigXN? NVXiSmZnSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBJ\UyjIHPlcIx{KGW6cILld5NqdmdiQ1S0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiMjDkZZl{KGK7IHLleIEu\2GuYXP0c5Nq\GG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyIE2gNE4xOjRizszNMi=> NGPkVpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOFkyQSd-MkSxNlQ6OTl:L3G+
MT-4 M2mzeWFvfGm4aYLhcEBie3OjeR?= NU\wPWo1SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYIEGgVmlPKEiLVjCxJHJKViCqYYLic5JqdmdiaX70[Ydz[XOnIHflcoUhcW6oZXP0[YQhcW5iTWStOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7IHHmeIVzKDRyIIDhd5Ni\2W|IIPlcIVkfGWmIHnuJJBz\XOnbnPlJI9nKGOxbYDveY5lNCCHQ{WwJF0hOC5yMkWg{txONg>? NFTtcXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3PFcyOyd-MUizO|g4OTN:L3G+
TZM-bl NXfrRoVCSW62aY\pdoFtKGG|c3H5 MV20PEBpenN? NInXfnVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaX7m[YN1\WRiaX6gbJVu[W5iVGrNMYJtKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHnueoVzfGWmIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nzMEBGSzVyIE2gNE4xOjVizszNMi=> NWS5b5A1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVQ4PjJpPkKyNVU1PzZ{PD;hQi=>
MT4 MoTHSpVv[3Srb36gZZN{[Xl? M{nRbVEhcHJ? NYThbVVnUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgTGlXOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgeZNqdmdiY3XscJMheHKnLXnuZ5Vj[XSnZDD3bZRpKGOxbYDveY5lKG[xcjCxJIhzKG2nYYP1doVlKDRiZHH5d{Bxd3O2II\pdoFtKGmwZnXjeIlwdiCrbjDwdoV{\W6lZTDv[kAzOCCvZz;tcEBJW0FiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xOjlizszNMi=> M3LtSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[zNVM2Lz5{Mkm2N|E{PTxxYU6=
P4R5 MAGI MmrZRY51cX[rcnHsJIF{e2G7 NYTGRWE2OjRiaILz MkTQRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCrbn\lZ5Rm\CCrbjDDSFQwS1iFUkSvR2NTPSCneIDy[ZN{cW6pIHj1cYFvKFB2UkWgUWFIUSClZXzsd{BxemWrbnP1ZoF1\WRid3n0bEBk\WyuczDmc5IhOjRiaILzJIZwdGyxd3XkJIJ6KH[rcnHsJIlv\mWldHnvckBu\WG|dYLl[EBi\nSncjC0PEBpenNiYomgZoV1[S2pYXzhZ5Rwe2mmYYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjB|IN88UU4> NIrNc2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECzNVk4Pid-M{CwN|E6PzZ:L3G+
P4R5 Mni2RY51cX[rcnHsJIF{e2G7 NF3pe2czPCCqcoO= MnH0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCrbn\lZ5Rm\CCrbjDDSFQwS1iFUkSvR2NTPSCneIDy[ZN{cW6pIHj1cYFvKFB2UkWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCycnXpcoN2[mG2ZXSge4l1cCClZXzsd{Bnd3JiMkSgbJJ{KG[xbHzve4VlKGK7II\pdoFtKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkh[mW2YT3nZYxi[3Sxc3nkZZNmKHKncH;yeIVzKGenbnWgZZN{NCCHQ{WwJF0hOC5yMzFOwG0v MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{NUK3PUc,Ojh3MkWyO|k9N2F-
P4R5 NGW5OGtCdnSrdnnyZYwh[XO|YYm= NXr1fpJFOjRiaILz NVT3PXNkSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDpcoZm[3SnZDDpckBpfW2jbjDQOHI2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjD2bZJidCCrbn\lZ5Rqd25icILlbY5kfWKjdHXkJJdqfGhiY3XscJMh\m:{IEK0JIhzeyCob3zsc5dm\CCkeTD2bZJidCCrbn\lZ5Rqd25ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KG[udX;y[ZNk\W6lZTDiZZNm\CCkZYThMYdidGGldH;zbYRie2VicnXwc5J1\XJiZ3Xu[UBj[XOnZDDNRWdKKGG|LDDFR|UxKD1iMD6wN{DPxE1w NV7qcXF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwN|ExPjJpPkK5NFMyODZ{PD;hQi=>
P4R5 MnTwRY51cX[rcnHsJIF{e2G7 NGnLSG4zPCCqcoO= M3foTGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXi1zIHnu[oVkfGWmIHnuJIh2dWGwIGC0VlUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwII\pdoFtKHKncHzpZ4F1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiMkSgbJJ{KG[xbHzve4VlKGK7II\pdoFtKGmwZnXjeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IF3BS2kh[XO|YYmsJGVEPTBiPTCwMlA{KM7:TT6= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODd|OUiyNkc,OzB5M{m4NlI9N2F-
P4R5 MVHBcpRqfmm{YXygZZN{[Xl? MXuyOEBpenN? NHjh[pVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHnu[oVkfGWmIHnuJIh2dWGwIGC0VlUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oII\pdpV{KHKncHzpZ4F1cW:wIIDy[Ylv[3WkYYTl[EB4cXSqIHPlcIx{KG[xcjCyOEBpenNiZn;scI94\WRiYomgeolz[WxiaX7m[YN1cW:wIH\vdkA1QCCqcoOgZpkhPC2vZYTofYx2dWKnbHzp[oVzgWypYXzhZ5Rwe2mmZT3iZZNm\CCPQVfJJIF{e2G7LDDFR|UxKD1iMD6wN{DPxE1w M3\rV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkizNlYyLz5{N{K4N|I3OTxxYU6=
MT4 NXLsT4UySW62aY\pdoFtKGG|c3H5 M3rWcWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY4hcHWvYX6gUXQ1KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEWwKUBvd3KvYXygbJVu[W5ic3XyeY0tKEmFOUWgQUAxNjB|MTFOwG0v NVn3XXFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OlM4PTFpPkG4O|Y{PzVzPD;hQi=>
MT4 NYTqPXVKSW62aY\pdoFtKGG|c3H5 NGjHUJo1QCC2bzC3NkBpenN? NGDXVoFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDlfJBz\XO|aX7nJGdHWCCrbnP1ZoF1\WRiZn;yJFQ5KHSxIEeyJIhzeyCrbjDwdoV{\W6lZTDv[kA2OCVibn;ycYFtKGi3bXHuJJNmenWvIHL5JI12dHSrcHzlJJJwfW6mII\pdoFtKHKncHzpZ4F1cW:wIHvpcoV1cWO|IHHzd4F6NCCLUDC9JFAvODV|IN88UU4> M3W4R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3PVY2Lz5{NkO5O|k3PTxxYU6=
BL21(DE3) M2rxbmZ2dmO2aX;uJIF{e2G7 NGntcmcyKGi{ MVjJcohq[mm2aX;uJI9nKEyHRFfGM5A4PS2mZYDlcoRmdnRiZoXscEBt\W6pdHigTGlXNTFiaX70[Ydz[XOnIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEGgbJIh\nW{dHjldkBqdmO3YnH0[YQh\m:{IEmwJI1qdnNid3n0bEBjcW:2aX6tcIFj\WynZDDkc45weiCGTlGgZY5lKHSjcnfleEBFVkFiYomgTHRTTiCjc4PhfUwhUUN3MDC9JFAvODV6IN88UU4> M1\5UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNESyOlg1Lz5|MUS0NlY5PDxxYU6=
MT-4 NWnTW3RVSW62aY\pdoFtKGG|c3H5 MmjBRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXKDFiUlnOJGhKXiBzIGLJUkBp[XKkb4LpcochcW62ZXfyZZNmKGenbnWgbY5n\WO2ZXSgbY4hVVRvNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZpkhVVSWIHHzd4F6KGGodHXyJFYxKHCjc4Ph[4V{KHOnbHXjeIVlKGmwIIDy[ZNmdmOnIH;mJINwdXCxdX7kMEBGSzVyIE2gNE4xPjhizszNMi=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5OEexN{c,OTh|N{i3NVM9N2F-
HeLaT4 MoWzRY51cX[rcnHsJIF{e2G7 NXvEVpA5SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qhe2mwZ3zlMZJwfW6mIFjJWlEhVky[Llz1fE1TKGijcnLvdolv\yCrbnHjeIl3[XSrbnegcZV1[XSrb37zJIlvKGWwdjygepBzKGGwZDDjZZJzcWW|IH\pdoVndHlibIXjbYZmemG|ZTDn[Y5mKGmwIIDsZYNmKG:oIH7l[kBie3Onc4Pl[EBieyCuZY\lcEBw\iB{IH3pcpMhdWGpbnX0bYMhdmGwb4DhdpRq[Wy|LX3l[IF1\WRiaX7m[YN1cW:wIHnuJIh2dWGwIFjlUIFVPCClZXzsd{B1emWjdHXkJIZweiBzLDDFR|kyKD1iMD6wO|Mh|ryPLh?= MmexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyNkCxNFgoRjJzME[wNVA5RC:jPh?=
HeLa-T4 M2PQbmFvfGm4aYLhcEBie3OjeR?= M2XaOFQ5KGi{cx?= M4q0ZmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJNqdmeuZT3yc5Vv\CCKSW[xJG5NYC6OdYitVkBp[XKkb4LpcochcW6jY4TpeoF1cW6pIH31eIF1cW:wczDpckBmdnZuII\wdkBidmRiY3HydolmeyCoaYLl[ox6KGy3Y3nm[ZJie2ViZ3Xu[UBqdiCybHHj[UBw\iCwZX[gbY5n\WO2ZXSgbY4hcHWvYX6gTIVN[S2WNDDj[YxteyCjc4Pld5Nm\CCjczDseYNq\mW{YYPlJIFkfGm4aYT5JIFnfGW{IES4JIhzeyCkeTDlfI9o\W6xdYOgVnQh[XO|YYmsJGVEPTBiPTCwMlA4PyEQvF2u M1vOW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzME[wNVA5Lz5{MUC2NFExQDxxYU6=
TZM-bl M{T0cmFvfGm4aYLhcEBie3OjeR?= Mn7rOFghcHK| M1jRPGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXi1zIHnu[oVkfGWmIHnuJIh2dWGwIGTaUU1jdCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIILldIxq[2G2aX;uJIZweiB2ODDodpMh[nliYoLp[4h1NUeubzDseYNq\mW{YYPlJIF{e2G7LDDFR|UxKD1iMD6xOUDPxE1w NUPFbo9ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0PFc6OTNpPkK2OFg4QTF|PD;hQi=>
HOS MkWzRY51cX[rcnHsJIF{e2G7 NHXXT2I{KGi{cx?= M{XOTWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCqYYLic5JqdmdiaX70[Ydz[XOnIF6xOVVJKG23dHHueEBqdm[nY4Tl[EBqdiCKT2OgZ4VtdHNicILlbY5kfWKjdHXkJIZweiB|IHjyd{Bnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgOFghcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMUW0JO69VS5? MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4NVYoRjJ2NEexPFE3RC:jPh?=
TZM-bl Mnz5RY51cX[rcnHsJIF{e2G7 M{DXS2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MlMhcW6oZXP0[YQhcW5iaIXtZY4hXFqPLXLsJINmdGy|IH3lZZN2emWmIIXweI8hOjRiaILzJIJ6KGK{aXfoeEBIdG9vbIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4yPiEQvF2u M4TSNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUW3OlA6Lz5|MUW1O|YxQTxxYU6=
HOS MnjrRY51cX[rcnHsJIF{e2G7 MmHNN{BpenN? NHXDO5pCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaHHyZo9zcW6pIHnueIVoemG|ZTDZNVQ{WiCvdYThcpQhcW6oZXP0[YQhcW5iSF;TJINmdGy|IIDy[Ylv[3WkYYTl[EBnd3JiMzDodpMh\m:ubH;3[YQh[nlidnnyZYwhcW6oZXP0bY9vKG2nYYP1doVlKGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkG2NkDPxE1w NFvSXms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVgyPid-MkS0O|E5OTZ:L3G+
TZM-bl NGfmW3NCdnSrdnnyZYwh[XO|YYm= NFLMVpcyKGi{ NXHDdY1mSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQvOyCrbn\lZ5Rm\CCrbjDoeY1idiCWWl2tZowh[2WubIOg[ZhxemW|c3nu[{BEYEOUND30do9xcWNiaX7jeYJifGWmIH\vdkAyKGi{IIDybY9zKHSxIHnu[oVkfGmxbjDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE42KM7:TT6= MnPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUGwOFIoRjJ2MkmxNFQzRC:jPh?=
TZM-bl NV:5Xo5GSW62aY\pdoFtKGG|c3H5 MVexJIhz MnvIRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTESuN{Bqdm[nY4Tl[EBqdiCqdX3hckBVYk1vYnygZ4VtdHNiZYjwdoV{e2mwZzDDXGNTPC22cn;wbYMhcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJJRwKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD61NFEyQSEQvF2u MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7MUC0Nkc,OjR{OUGwOFI9N2F-
HeLa-T4 NVrZeoVqSW62aY\pdoFtKGG|c3H5 MUW0PEBpenN? NIXuNINCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB{cW6pbHWtdo92dmRiSFnWNUBPVFhwTIX4MXIhcGG{Yn;ybY5oKGmwYXP0bZZifGmwZzDteZRifGmxboOgbY4h\W64LDD2dJIh[W6mIHPhdpJq\XNiZnny[YZtgSCudXPp[oVz[XOnIHflcoUhcW5icHzhZ4Uhd2ZibnXmJIlv\mWldHXkJIlvKGi3bXHuJGhmVGFvVESgZ4VtdHNiYYPz[ZN{\WRiYYOgcJVkcW[ncnHz[UBi[3Srdnn0fUBi\nSncjC0PEBpenNiYomg[Zhw\2Wwb4XzJHJVKGG|c3H5MEBGSzl3IE2gNE45OSEQvF2u MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB4MEGwPEc,OjFyNkCxNFg9N2F-
HOS Mo[xRY51cX[rcnHsJIF{e2G7 NIrXdos{KGi{cx?= M3HURWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCqYYLic5JqdmdiaX70[Ydz[XOnIFexOFBUN1FzNEjIJIRwfWKuZTDteZRidnRiaX7m[YN1\WRiaX6gTG9UKGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgN{BpenNiZn;scI94\WRiYomgeolz[WxiaX7m[YN1cW:wIH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTBiPTCxMlkh|ryPLh?= MnSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4NVYoRjJ2NEexPFE3RC:jPh?=
MT2 MlHKRY51cX[rcnHsJIF{e2G7 MX2zJJRwKDRiZHH5dy=> M4PCT2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MVMhcGG{Yn;ybY5oKEdzNEDTM3EyPDiKIH31eIFvfCCrbn\lZ5Rm\CCrbjDoeY1idiCPVEKgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyC2bzC0JIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOi52MjFOwG0v NXOwUHJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{KwPFExOTBpPkOyNFgyODFyPD;hQi=>
HeLaT4 MnPqRY51cX[rcnHsJIF{e2G7 NYjlcmN2OjRiaILz Mke0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4lv\2ynLYLveY5lKEiLVkGgUmxZNky3eD3SJIhiemKxcnnu[{BqdmGldHn2ZZRqdmdibYX0ZZRqd26|IHnuJIVvfixidoDyJIFv\CClYYLybYV{KG[rcnXmcJkhdHWlaX\ldoF{\SCpZX7lJIlvKHCuYXPlJI9nKG6nZjDhd5Nme3OnZDDhd{Bt\X[nbDDv[kBqdm[nY4Tpc44hfXOrbnegbJVu[W5iSHXMZXQ1KGOnbHzzJJBz\XS{ZXH0[YQh\m:{IEK0JIhzeyCob3zsc5dm\CCkeTDlfJBwe2WmIITvJJZqNCCHQ{WwJF0hPC54IN88UU4> NVHKXFJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOlAyODhpPkKxNFYxOTB6PD;hQi=>
MT4 M1HWWWN6fG:2b4jpZ4l1gSCjc4PhfS=> MYS1JIRigXN? NYjQcFNpS3m2b4TvfIlkcXS7IHnuJI1w[2tvaX7m[YN1\WRiaIXtZY4hVVR2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDViZHH5d{BjgSCPVGSgZZN{[XluIFPDOVAhRSB4LkWxJO69VS5? Mm\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF|MkS1OlIoRjNzM{K0OVYzRC:jPh?=
CHO MW\GeY5kfGmxbjDhd5NigQ>? MUDJcohq[mm2aX;uJI9nKHOub4eg[IVt[XmnZDDpcpdiemRicnXjeIlngWmwZzDwc5Rie3OrdX2gZ5VzemWwdDCoTYt{MSCrbjDDbIlv\XOnIFjhcZN1\XJiT4\hdpkhMEOKTzmgZ4VtdHNiZYjwdoV{e2mwZzDoT5ZNWVRzL3jtbY5MKG2nYYP1doVlKHW|aX7nJGlwdlexcnvzJHF2[XS2cn:gZZV1d22jdHXkJJBifGOqIHPsZY1xKHCuYYTmc5JuNCCLQ{WwJF0hOjVwMUG4PUDPxE1w Mn;tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyOEe3OVMoRjJ3MEi3O|U{RC:jPh?=
U373-MAGI M4H5UGFvfGm4aYLhcEBie3OjeR?= MWO1NEBweiBzMECgcm0> NHXub5Q4OiCqcoO= M3XobGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4FoKGyndnXsJIF1KDVyIH;yJFExOCCwTTDt[YF{fXKnZDDheEA4OiCqcoOgdI9{fCCrbn\lZ5Rqd25iYomgdXBEWiCvZYToc4Q> M{PKdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI MWPBcpRqfmm{YXygZZN{[Xl? NX25TYJ4PTBib4KgNVAxKG6P NGfNN5A4OiCqcoO= Ml3ERY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDVOU1o[WdibHX2[Ywh[XRiNUCgc5IhOTByIH7NJI1m[XO3cnXkJIF1KDd{IHjyd{Bxd3O2IHnu[oVkfGmxbjDifUByWEOUIH3leIhw\A>? NVjRSJFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
MT2 MX\BcpRqfmm{YXygZZN{[Xl? NWjMNll7OSC3TR?= NVzNUHpwOzBiaILz M3vS[GFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJdqdGRvdInw[UBJUVZzIF7MOE0{KGmwZnXjeIVlKGmwZnXjeIVlKGmwIHj1cYFvKE2WMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hUEmYMTDpcpRm\3KjdHXkJGRPSSCjdDCxJJVOKGGwZDDt[YF{fXKnZDDh[pRmeiB|MDDodpMheG:|dDDpcoZm[3Srb36gZpkhSWy3LVzUVkBRS1JicILveI9kd2xiYnHz[YQhdWW2aH;k NF3TOXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm5Olc5OCd-M{C5PVY4QDB:L3G+
Assay
Methods Test Index PMID
Western blot CHOP / ATF-4 / XBP-1 / Lamin B 24625618
In vivo Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy. [5]

Protocol (from reference)

Kinase Assay:

[1]

  • PFV integration assay:

    For quantitative strand transfer assays, donor DNA substrate is formed by annealing HPLC grade oligonucleotides 5′-GACTCACTATAGGGCACGCGTCAAAATTCCATGACA and 5′-ATTGTCATG GAATTTTGACGCGTGCCCTATAGTGAGTC. Reactions (40 μL) contains 0.75 μM PFV IN, 0.75 μM donor DNA, 4 nM (300 ng) supercoiled pGEM9-Zf(−) target DNA, 125 mM NaCl, 5 mM MgSO4, 4 μM ZnCl2, 10 mM DTT, 0.8% (vol/vol) DMSO, and 25 mM BisTris propane–HCl, pH 7.45. Raltegravir is added at indicated concentrations. Reactions are initiated by addition of 2 μL PFV IN diluted in 150 mM NaCl, 2 mM DTT, and 10 mM Tris-HCl, pH 7.4, and stopped after 1 hour at 37 °C by addition of 25 mM EDTA and 0.5% (wt/vol) SDS. Reaction products, deproteinized by digestion with 20 μg proteinase K for 30 minutes at 37 °C followed by ethanol precipitation, are separated in 1.5% agarose gels and visualized by staining with ethidium bromide. Integration products are quantified by quantitative real-time PCR, using Platinum SYBR Green qPCR SuperMix and three primers: 5′-CTACTTACTCTAGCTTCCCGGCAAC, 5′-TTCGCCAGTTAATAGTTTGCGCAAC, and 5′-GACTCACTATAGGGCACGCGT. PCR reactions (20 μL) contained 0.5 μM of each primer and 1 μL diluted integration reaction product. Following a 5-min denaturation step at 95 °C, 35 cycles are carried out in a CFX96 PCR instrument, using 10 seconds denaturation at 95 °C, 30 seconds annealing at 56 °C and 1 minutes extension at 68 °C. Standard curves are generated using serial dilutions of WT PFV IN reaction in the absence of INSTI.

Cell Research:

[5]

  • Cell lines: Human MT-4 cells
  • Concentrations: 0.0001-1 μM
  • Incubation Time: 5 days
  • Method:

    Human MT-4 cells are infected for 2 hours with the SIVmac251, HIV-1 (IIIB) and HIV-2 (CDC 77618) stocks at a multiplicity of infection of, approximately, 0.1. Cells are then washed three times in phosphate buffered saline, and suspended at 5 × 105/mL in fresh culture medium (to primary cells 50 units/mL of IL-2 are added) in 96-well plates, in the presence or absence of a range of triplicate raltegravir concentrations (0.0001 μM -1 μM). Untreated infected and mock-infected controls are prepared too, in order to allow comparison of the data derived from the different treatments. Viral cytopathogeniciy in MT-4 cells is quantitated by the methyl tetrazolium (MTT) method (MT-4/MTT assay) when extensive cell death in control virus-infected cell cultures is detectable microscopically as lack of capacity to re-cluster. The capability of MT-4 cells to form clusters after infection. Briefly, clusters are disrupted by pipetting; and, after 2 hours of incubation at 37 °C, the formation of new clusters is assessed by light microscopy (100 × magnification). Cell culture supernatants are collected for HIV-1 p24 and HIV-2/SIVmac251 p27 core antigen measurement by ELISA. In CEMx174-infected cell cultures, which show a propensity to form syncytia induced by the virus envelope glycoproteins, syncytia are counted, in blinded fashion, by light microscopy for each well at 5 days following infection.

Animal Research:

[5]

  • Animal Models: Indian Rhesus macaques
  • Dosages: 50 mg/kg or 100 mg/kg
  • Administration: Oral administration

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

8mg/mL

Chemical Information

Molecular Weight 444.42
Formula

C20H21FN6O5

CAS No. 518048-05-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04513626 Recruiting Drug: DORAVIRINE 100 MG [Pifeltro] HIV Infections Centre de Recherches et d''Etude sur la Pathologie Tropicale et le Sida September 15 2020 Phase 2
NCT03667547 Completed Drug: Raltegravir Human Immunodeficiency Virus (HIV) Infection Merck Sharp & Dohme LLC September 27 2018 Phase 4
NCT03174977 Recruiting Drug: 18F-Raltegravir HIV-1-infection University of California San Francisco|Merck Sharp & Dohme LLC April 1 2018 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy MK-0518|MK-0518 ic50|MK-0518 price|MK-0518 cost|MK-0518 solubility dmso|MK-0518 purchase|MK-0518 manufacturer|MK-0518 research buy|MK-0518 order|MK-0518 mouse|MK-0518 chemical structure|MK-0518 mw|MK-0518 molecular weight|MK-0518 datasheet|MK-0518 supplier|MK-0518 in vitro|MK-0518 cell line|MK-0518 concentration|MK-0518 nmr|MK-0518 in vivo|MK-0518 clinical trial|MK-0518 inhibitor|MK-0518 Microbiology inhibitor